MENU
+Compare
CTMX
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$3.85
Change
-$0.37 (-8.75%)
Capitalization
654.02M

CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more

Industry: #Biotechnology
CTMX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CTMX with price predictions
Nov 12, 2025

Aroon Indicator for CTMX shows an upward move is likely

CTMX's Aroon Indicator triggered a bullish signal on November 12, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 115 similar instances where the Aroon Indicator showed a similar pattern. In of the 115 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2025. You may want to consider a long position or call options on CTMX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CTMX just turned positive on November 04, 2025. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CTMX moved out of overbought territory on November 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where CTMX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CTMX broke above its upper Bollinger Band on November 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.090) is normal, around the industry mean (24.439). P/E Ratio (12.867) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (4.011) is also within normal values, averaging (322.723).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CTMX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CTMX is expected to report earnings to fall 41.67% to -5 cents per share on March 04

CytomX Therapeutics CTMX Stock Earnings Reports
Q4'25
Est.
$-0.05
Q3'25
Missed
by $0.04
Q2'25
Beat
by $0.06
Q1'25
Beat
by $0.21
Q4'24
Beat
by $0.43
The last earnings report on November 06 showed earnings per share of -9 cents, missing the estimate of -5 cents. With 3.87M shares outstanding, the current market capitalization sits at 654.02M.
A.I. Advisor
published General Information

General Information

an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
122
Web
https://www.cytomx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PZVIX12.980.07
+0.54%
Pzena International Small Cap Value Inv
HFQIX7.210.03
+0.42%
Janus Henderson Global Equity Income I
WMLIX36.970.03
+0.08%
Wilmington Large-Cap Strategy Instl
FAPJX14.05N/A
N/A
Fidelity Advisor Healthy Future A
VLIFX35.05-0.02
-0.06%
Value Line Mid Cap Focused

CTMX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
+3.17%
MLEC - CTMX
42%
Loosely correlated
-3.30%
BGMS - CTMX
38%
Loosely correlated
+2.86%
BCAB - CTMX
37%
Loosely correlated
+0.84%
HOWL - CTMX
36%
Loosely correlated
-3.54%
VCYT - CTMX
36%
Loosely correlated
-0.84%
More